N@N

Spectral Molecular Imaging Inc. Chief Executive Officer Featured as a Guest on MoneyTV This Week

^{Published on 2010-08-06 13:22:16 - Market Wire}
 

BEVERLY HILLS, Calif.--([ BUSINESS WIRE ])--Spectral Molecular Imaging, a wholly-owned subsidiary of Cascade Technologies, Inc. (OTCBB: CSDT), announced that its Chairman and CEO, Dr. Daniel L. Farkas, appeared this week on MoneyTV to describe the companya™s proprietary technology and to outline its strategy of developing a line of optical imaging devices for earlier detection of cancer, particularly melanoma.

"Light is a rich investigational tool and while endoscopy has been quite successful, we believe that we can do better"

Advanced real time imaging technology for early cancer detection.

Dr. Farkas noted that "by using hyperspectral imaging technology we hope to develop and provide the medical profession with an advanced early detection tool that can help to alleviate human suffering and save lives. For example," he explained, "the American Cancer Society reported that for 2007 there were almost 60,000 cases of melanoma just in the United States -- it is one of our fastest growing and most dangerous cancers. Yet with early detection we can hope for a 100% cure rate, while late detection is almost always fatal."

He went on to relate that "our imaging device under development, which we call SkinSpecta", is designed to enable the live, real-time identification and analysis of molecular, cellular and tissue features indicating cancer and other serious conditions, much earlier and more accurately than currently possible."

aLight is a rich investigational tool and while endoscopy has been quite successful, we believe that we can do better," Dr. Farkas asserted. aOur goal," he reiterated, "is for SkinSpecta" and our other devices to become part of the standard of care in cancer detection, significantly improving patient outcomes while lowering healthcare costs.a

The entire interview on the MoneyTV program can be viewed online at [ www.moneytv.net ]. Investors interested in learning more about SMIa™s technology and product development can also view or download the Investor Information Brief at the companya™s website, [ http://www.spectralmi.com ].

About Spectral Molecular Imaging

Spectral Molecular Imaging, Inc., a wholly-owned subsidiary of Cascade Technologies, Inc., is a development-stage, medical imaging device company. Application of SMIa™s proprietary spectral-optical imaging technologya"originally developed for satellite reconnaissancea"is expected to advance the diagnoses of cancer and precancerous conditions. SMI is developing non-invasive imaging systems using its patented technology for improved clinical diagnostics, primarily in the field of cancer pathology. SMIa™s devices utilize high-resolution imaging, identification, and analysis of certain molecular, cellular, and tissue features via patented spectral-imaging approaches. We also intend to provide services related to our primary products, including software modules and maintenance services, and to develop optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time. Our technology is expected to enable early detection and more reliable diagnosis of various diseases, including skin cancers such as melanoma, Barretta™s esophagus (a condition caused by chronic acid reflux that can lead to esophageal cancer) and lung cancer. The development of this technology is expected to significantly improve long-term patient outcomes while substantially reducing overall costs for the healthcare system. For more information, please visit [ http://www.spectralmi.com ].

Forward-Looking Statements

The content of this news announcement contains or may contain certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in filings made by Cascade Technologies, Inc., SMI's parent, with the Securities and Exchange Commission. Forward-looking statements may include, without limitation, statements regarding SMI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. These statements are based upon the current beliefs and expectations of SMI's management; however, actual results, including, without limitation, actual sales and other financial results, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve risks and uncertainties that are subject to change based on various factors, many of which are beyond SMI's control.